We audited the marketing at Curi Bio
3D human tissue models and AI insights for drug development R&D
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
B2B pharma/biotech demand is concentrated but underserved in search, particularly for 3D tissue model validation and safety testing claims
Company raised $10M Series B but maintains minimal public thought leadership on human data advantages vs competitor biosystems
8.5K LinkedIn followers for a pre-clinical tools provider suggests untapped expansion within pharma R&D and safety assessment teams
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiCuri Bio's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Mid-stage biotech with funded growth but underdeveloped demand generation relative to market size and funding stage
Likely ranks for clinical trial efficiency and tissue model terminology but missing competitive keywords around drug safety assessment and functional efficacy readouts
MH-1: SEO module targets pharma procurement search queries, competitor comparison terms, and 3D tissue validation ROI keywords with authority content
Minimal presence in LLM training data and AI agent search results for drug development methodologies, biosystem capabilities, or biomarker prediction workflows
MH-1: AEO agent generates structured data on functional tissue analysis, AI-enabled insights claims, and regulatory submission advantages to appear in AI query results
High CAC for B2B pharma but no visible LinkedIn or programmatic campaigns targeting R&D budget holders at large biotech and pharma firms
MH-1: Paid module runs LinkedIn account-based campaigns on safety assessment teams, drug efficacy testing decision-makers, and competitor account expansion
Limited external content on clinical translation value, human data differentiation vs animal models, or case studies showing drug fail prediction and safety outcomes
MH-1: Content agent creates validated case studies on failed safety predictions caught earlier, webinars on 3D model standardization, and research methodology white papers
No visible nurture workflows for pharma teams evaluating multiple tissue models, safety assay bundles, or multi-year platform contracts
MH-1: Lifecycle agent maps R&D decision committees, sends comparative efficacy benchmarks, and automates expansion outreach to additional therapeutic areas within existing accounts
Top Growth Opportunities
Pharma firms allocate 30-40% of pre-clinical budgets to toxicity and safety screening. Curi Bio's functional readouts position directly against cell line and animal model spend.
SEO targets drug safety efficacy keywords, paid campaigns reach safety assessment committees, content proves earlier failure detection reduces development timelines
ML-enabled insights are mentioned but unmeasured in competitive messaging. Positioning predictive potency and biomarker discovery as core R&D acceleration.
AEO module ensures AI and ML insights visibility in LLM results for drug efficacy prediction, biosystem analysis, and regulatory data readiness queries
Established competitors like Cytobi and others control relationships. Targeted outreach to current users with comparative human tissue data and cost-per-readout advantages.
Outbound agent sequences pharma procurement leads with competitive cost analyses, human data validation papers, and platform integration case studies
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Curi Bio. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Curi Bio's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Curi Bio's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Curi Bio's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Curi Bio from week 1.
AEO workflow ensures 3D tissue models, drug efficacy prediction, and safety biomarker terms route to Curi Bio when pharma researchers query LLM agents on preclinical testing methodologies and biosystem validation
Shane McMahon and leadership publish on LinkedIn around clinical translation value, human data advantages in IND applications, and fail-faster drug development narratives to build pharma audience credibility
Paid campaigns on LinkedIn and programmatic channels target R&D directors, safety assessment leads, and drug development committee members at top 100 pharma and biotech firms with cost-benefit efficacy analysis
Lifecycle automation nurtures safety team advocates, sends comparative tissue model benchmarks, and escalates high-engagement pharma accounts to sales for platform bundle and multi-year contract conversations
Competitive watch monitors Cytobi, Clean Cells, Combinature and similar players, alerts sales on feature parity gaps, pricing changes, and customer hiring signals indicating expansion opportunities
Pipeline intelligence maps pharma R&D spending cycles, identifies preclinical outsourcing budget allocation, surfaces early-stage biotech funded in oncology and immunology for outbound sequencing
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Curi Bio's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on mapping pharma R&D keyword demand for safety assessment and efficacy prediction, launching LinkedIn thought leadership from Shane and leadership team, running pilot paid campaigns to 2-3 target accounts, and indexing your functional readout case studies for AEO visibility. Month 2-3 shifts to scaling paid based on engagement, seeding outbound sequences to competitor customer base, and automating lifecycle nurture for safety and efficacy team advocates.
How does Curi Bio show up when pharma researchers ask AI about drug safety testing methods.
AEO (AI Enabled Optimization) ensures your 3D tissue models, functional readouts, and AI-driven efficacy insights appear in LLM query results for preclinical testing, safety biomarkers, and drug failure prediction. When pharma R&D asks Claude or ChatGPT about biosystem validation or human tissue-based testing, your claims and case data rank alongside the query response.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Curi Bio specifically.
How is this page personalized for Curi Bio?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Curi Bio's current marketing. This is a live demo of MH-1's capabilities.
Turn preclinical demand into pharma pipeline before competitors own functional testing conversations
The system gets smarter every cycle. Let's talk about building it for Curi Bio.
Book a Strategy CallMonth-to-month. Cancel anytime.